Yang Li
李阳
Yang Li is a biotech entrepreneur and the co-founder and chairman of ReviR Therapeutics, an AI-driven RNA therapeutics company . He helped establish the firm in the early 2020s to develop oral gene therapies targeting neurological diseases at the RNA level, combining AI, RNA biology, and high-throughput drug screening . As of mid-2024, ReviR was transitioning from platform-building to clinical-stage development . Beyond his role at ReviR, Yang Li has appeared as a speaker in 5Y Capital forums on computational drug discovery . Elsewhere's corpus does not cover his prior career history or educational background in detail.
AI-generated — may contain errors, please verify.
Coverage
5Y News | 5Y Capital Portfolio Company ReviR Therapeutics Raises $30 Million in Series A Funding
Continuing to advance "oral gene therapy" through AI+RNA.
5Y News | AI+RNA Startup ReviR Therapeutics Closes Tens of Millions of Dollars in Pre-A Round
Using AI algorithms and gene technology to drive targeted RNA drug development.
5Y Talk | How Can Computing and AI Break Through the Traditional Paradigm of Drug Discovery?
Entering the Game, Direction, and the Future.
